Table 1.

Predictive data of eligibility and stability of TFR^19,39

Parameter	Impact on eligibility for TFR	Impact on stability of TFR	Study examples
Prognostic score	DMR more frequent in low-risk patients	TFR more stable in low-risk patients; risk of relapse high in high-risk patients	STIM, STIM2, ENESTfreedom, TWISTER
TKI type	DMR more frequent with 2G-TKIs vs imatinib	No major difference
Initial slope of BCR-ABL1 transcript decline or “halving time”	Probability of DMR better in patients with EMR	No major difference
MMR at 12 months	Probability of DMR better in patients with MMR	No major difference
Type of BCR-ABL1 transcript	DMR more likely in patients with e14a2 vs e13a2 (inconsistent)	TFR more stable with e14a2 (inconsistent)
Mutations outside BCR-ABL1	MMR and DMR more likely in patients lacking BCR-ABL1- independent mutations	Data still immature
Duration of DMR		Longer DMR predictive	EURO-SKI
Level of MR before stop		Probably yes; undetectable BCR-ABL1 predictive	EURO-SKI, ENESTfreedom
Duration of TKI therapy		Inconsistent, overlapping with duration of DMR	STIM
Proportion of natural killer cells		Reduced risk of relapse after imatinib and dasatinib but not after nilotinib

EMR, early molecular response.